Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mono-epitope anti-DLL3 ADC
- Development stage
- Preclinical
- Lead developer
- Helixon
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A mono-epitope anti-DLL3 antibody-drug conjugate (ADC) is a targeted therapeutic agent composed of a monoclonal antibody that binds to a single specific epitope on the Delta-like ligand 3 (DLL3) protein, linked to a potent cytotoxic payload. DLL3 is an inhibitory Notch ligand that is highly and selectively expressed in small cell lung cancer (SCLC) and various neuroendocrine carcinomas, while remaining largely absent in healthy tissues, making it an ideal target for ADCs. Upon binding to the cell surface DLL3, the ADC is internalized via endocytosis, and the cytotoxic agent is released—typically through linker cleavage or lysosomal degradation—to induce apoptosis in the tumor cell. While early mono-epitope ADCs like rovalpituzumab tesirine (Rova-T) faced challenges in clinical trials due to toxicity and limited efficacy, they established the proof-of-concept for DLL3-targeted delivery and serve as the benchmark for next-generation biparatopic or AI-optimized DLL3-targeted therapies.
- Other names
- mono-epitope DLL3 ADCmonospecific anti-DLL3 ADC
02
Targets
TOP1 (DNA Topoisomerase I)DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on mono-epitope anti-DLL3 ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mono-epitope anti-DLL3 ADC.